Myeloid cell leukemia-1 (Mcl-1) plays a pivotal role in the survival of hematologic and solid tumors, and is known as a substantial oncogene. Studies have demonstrated the altered expression of Mcl-1 has been linked to malignancy development and poor prognosis. In this research, we have studied the expression of Mcl-1 mRNA in myelodysplastic syndrome (MDS) patients and determined association with clinicopathological factors, MDS subgroups as well as international prognostic scoring system. Materials and Methods: The relative level of Mcl-1 was determined by real time quantitative real-time polymerase chain reaction and gene expression normalized to Glyceraldehyde-3-phosphate dehydrogenase. Results: Results indicated amplification of mRNA encoding Mcl-1 in 100% of the cases. The higher level of Mcl-1 existed in MDS patients compared with the healthy controls but there was no statistically difference of Mcl-1 expression between these groups. Fold change in gene expression was higher in advanced stage MDS, high risk MDS, cases with >5% blast and LDH >400 to their corresponding groups. In addition, the correlation between gene expression and cytogenetic prognostic subgroups was statistically significant (p=0.043).
Introduction
Myeloid cell leukemia-1 (Mcl-1) is encoded by the Mcl-1 gene. Alternative splicing of the gene leads to isoform 1 (longer gene product) and isoform 2 (shorter gene product) [1] . Isoform 1, an important pro-survival protein of the Bcl-2 gene family, is of fundamental importance to the development, differentiation, proliferation and tumorgenesis [2] . The protein promotes cells survival by binding and sequestering their pro-apoptotic counterparts (Bak, Bim, and Bid) and inhibiting the release of cytochrome-c from mitochondria [3] [4] [5] [6] . Following genotoxic stress, Mcl-1 is ubiquitinylated and rapidly degraded, therefore cells commit to apoptosis [7] . This protein plays a pivotal role in the survival of hematologic and solid tumors and is known as a substantial oncogene [8] . Overexpression of Mcl-1 has been observed in a broad range of human tumors including breast, prostate, ovarian and colorectal cancers, chronic myelogenous leukemia, multiple myeloma and others [9] [10] [11] [12] [13] . Studies have demonstrated that altered expression of Mcl-1 has been linked to malignancy development and poor prognosis [12, [14] [15] [16] [17] [18] 
Conventional cytogenetic analysis
Conventional cytogenetic investigation was carried out for 54 patients. Karyotypes were investigated according to the method previously described [21] .
Gene expression analysis
The relative level of Mcl-1 was determined by 
Results

Patient characteristics
Demographic and hematologic findings are (Fig.2) The researchers concluded that Mcl-1 is a BCR/ABL-dependent survival factor that can be used as a therapeutic target in CML [26] .
In the present study, we not only showed that level, but a shift in transcript in favor of a pro-apoptotic state [29] . With respect to the limited number of patients in our study, correlations which were found here should be examined in a larger study population.
Conclusion
In conclusion, our study revealed a correlation of 
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